The Venture Codex

Participated · Equity · Jul 2017

Diasome’s core technology is Hepatocyte Directed Vesicles (HDV), which preferentially deliver insulin to liver hepatocytes to better mimic mealtime hepatic insulin exposure. HDV-insulin is described as the most clinically advanced novel pre-meal insulin in the global insulin pipeline and is designed to make commercial insulin more physiological and effective. The company is conducting multiple human clinical trials, including the ISLE-1 Phase 2b study in Type 1 diabetes being run at more than 20 U.S. sites and nearing the end of enrollment. Diasome recently initiated patient enrollment in two additional Phase 2 Type 1 diabetes studies. The pipeline also includes a first-in-class oral compound for Type 2 diabetes based on a novel mechanism of action. Diasome will use the proceeds from the new funding to continue its clinical development program and general operations.